Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Overview

Journal Clin Med Insights Oncol

Publisher Sage Publications

Specialty Oncology

Date 2022 Nov 7

PMID 36338263

Authors

Galo Duque

Carlos Manterola

Tamara Otzen

Cristina Arias

Dennise Palacios

Miriann Mora

Bryan Galindo

Juan Pablo Holguin

Lorena Albarracin

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer (BC) is the most common neoplasm in women worldwide. Liquid biopsy (LB) is a non-invasive diagnostic technique that allows the analysis of biomarkers in different body fluids, particularly in peripheral blood and also in urine, saliva, nipple discharge, volatile respiratory fluids, nasal secretions, breast milk, and tears. The objective was to analyze the available evidence related to the use of biomarkers obtained by LB for the early diagnosis of BC.

Methods: Articles related to the use of biomarkers for the early diagnosis of BC due to LB, published between 2010 and 2022, from the databases (WoS, EMBASE, PubMed, and SCOPUS) were included. The MInCir diagnostic scale was applied in the articles to determine their methodological quality (MQ). Descriptive statistics were used, as well as determination of weighted averages of each variable, to analyze the extracted data. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) are described.

Results: In this systematic review (SR), 136 articles met the selection criteria, representing 17 709 patients with BC. However, 95.6% were case-control studies. In 96.3% of cases, LB was performed in peripheral blood samples. Most of the articles were based on microRNA (miRNA) analysis. The mean MQ score was 25/45 points. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) have been found.

Conclusions: The determination of biomarkers through LB is a useful mechanism for the diagnosis of BC. The analysis of miRNA in peripheral blood is the most studied methodology. Our results indicate that LB has a high sensitivity and specificity for the diagnosis of BC, especially in early stages.

Citing Articles

Potentialities and critical issues of liquid biopsy in clinical practice: An umbrella review.

Veronese N, Luchini C, Ciriminna S, Spinelli K, Fruscione S, Mattiolo P Transl Oncol. 2025; 52:102172.

PMID: 39817953 PMC: 11786759. DOI: 10.1016/j.tranon.2024.102172.

Random forest algorithm identifies miRNA signatures for breast cancer detection and classification from patient urine samples.

Maurer J, Rubner M, Kuo C, Klein B, Franzen J, Wittenborn J Ther Adv Med Oncol. 2024; 16:17588359241299563.

PMID: 39678737 PMC: 11645719. DOI: 10.1177/17588359241299563.

The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.

Olbromski M, Mrozowska M, Piotrowska A, Smolarz B, Romanowicz H Cancer Immunol Immunother. 2024; 73(8):136.

PMID: 38833004 PMC: 11150347. DOI: 10.1007/s00262-024-03701-w.

Optimization of Surface Functionalizations for Ring Resonator-Based Biosensors.

Ardoino N, Lunelli L, Pucker G, Vanzetti L, Favaretto R, Pasquardini L Sensors (Basel). 2024; 24(10).

PMID: 38793970 PMC: 11124806. DOI: 10.3390/s24103107.

Identification of Endometrial Cancer-Specific microRNA Biomarkers in Endometrial Fluid.

Yang J, Barkley J, Bhattarai B, Firouzi K, Monk B, Coonrod D Int J Mol Sci. 2023; 24(10).

PMID: 37240034 PMC: 10218319. DOI: 10.3390/ijms24108683.

References

Li M, Zou X, Xia T, Wang T, Liu P, Zhou X . A five-miRNA panel in plasma was identified for breast cancer diagnosis. Cancer Med. 2019; 8(16):7006-7017. PMC: 6853814. DOI: 10.1002/cam4.2572. View

Ali M, El Gayar D, Hany N, Ezzat A, Zeyada R . MicroRNA 21 and microRNA 10b: early diagnostic biomarkers of breast cancer in Egyptian females. J Egypt Natl Canc Inst. 2022; 34(1):16. DOI: 10.1186/s43046-022-00115-6. View

Nadeem F, Hanif M, Ahmed A, Jamal Q, Khan A . Clinicopathological features associated to MiRNA-195 expression in patients with breast cancer: Evidence of a potential biomarker. Pak J Med Sci. 2017; 33(5):1242-1247. PMC: 5673741. DOI: 10.12669/pjms.335.13008. View

Delmonico L, Silva Magalhaes Costa M, Gomes R, De Oliveira Vieira P, Da Silva A, Fournier M . Methylation profiling in promoter sequences of and ( ) genes in blood and cfDNA from women with impalpable breast lesions. Oncol Lett. 2020; 19(4):3003-3010. PMC: 7068365. DOI: 10.3892/ol.2020.11382. View

Oloomi M, Bouzari S, Mohagheghi M, Khodayaran-Tehrani H . Molecular markers in peripheral blood of Iranian women with breast cancer. Cancer Microenviron. 2012; 6(1):109-16. PMC: 3601212. DOI: 10.1007/s12307-012-0118-7. View

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

Matamala N, Vargas M, Gonzalez-Campora R, Minambres R, Arias J, Menendez P . Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 2015; 61(8):1098-106. DOI: 10.1373/clinchem.2015.238691. View

Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A . Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2012; 132(7):1602-12. DOI: 10.1002/ijc.27799. View

El-Ashmawy N, Hussien F, El-Feky O, Hamouda S, Al-Ashmawy G . Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer. Life Sci. 2020; 259:118193. DOI: 10.1016/j.lfs.2020.118193. View

10.

Raheem A, Abdul-Rasheed O, Al-Naqqash M . The diagnostic power of circulating micro ribonucleic acid 34a in combination with cancer antigen 15-3 as a potential biomarker of breast cancer. Saudi Med J. 2019; 40(12):1218-1226. PMC: 6969640. DOI: 10.15537/smj.2019.12.24712. View

11.

Guo L, Zhang Q . Decreased serum miR-181a is a potential new tool for breast cancer screening. Int J Mol Med. 2012; 30(3):680-6. DOI: 10.3892/ijmm.2012.1021. View

12.

Hamam R, Ali A, Alsaleh K, Kassem M, Alfayez M, Aldahmash A . microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep. 2016; 6:25997. PMC: 4867432. DOI: 10.1038/srep25997. View

13.

Radwan W, Moussa H, Essa E, Kandil S, Kamel A . Peripheral blood mammaglobin gene expression for diagnosis and prediction of metastasis in breast cancer patients. Asia Pac J Clin Oncol. 2012; 9(1):66-70. DOI: 10.1111/j.1743-7563.2012.01556.x. View

14.

Zhang X, Zhao D, Yin Y, Yang T, You Z, Li D . Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis. NPJ Breast Cancer. 2021; 7(1):106. PMC: 8367945. DOI: 10.1038/s41523-021-00316-7. View

15.

Zou X, Xia T, Li M, Wang T, Liu P, Zhou X . MicroRNA profiling in serum: Potential signatures for breast cancer diagnosis. Cancer Biomark. 2020; 30(1):41-53. DOI: 10.3233/CBM-201547. View

16.

Tellez-Gabriel M, Knutsen E, Perander M . Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies. Int J Mol Sci. 2020; 21(24). PMC: 7763984. DOI: 10.3390/ijms21249457. View

17.

Farina N, Ramsey J, Cuke M, Ahern T, Shirley D, Stein J . Development of a predictive miRNA signature for breast cancer risk among high-risk women. Oncotarget. 2018; 8(68):112170-112183. PMC: 5762501. DOI: 10.18632/oncotarget.22750. View

18.

Li X, Tang X, Li K, Lu L . Evaluation of Serum MicroRNAs (miR-9-5p, miR-17-5p, and miR-148a-3p) as Potential Biomarkers of Breast Cancer. Biomed Res Int. 2022; 2022:9961412. PMC: 8803421. DOI: 10.1155/2022/9961412. View

19.

Ahmed I, Pusch C, Hamed T, Rashad H, Idris A, Abou El-Fadle A . Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA. Cancer Genet Cytogenet. 2010; 199(2):96-100. DOI: 10.1016/j.cancergencyto.2010.02.007. View

20.

Ramadan R, Desouky L, Elnaggar M, Moaaz M, Elsherif A . Association of DNA repair genes XRCC1 (Arg399Gln), (Arg194Trp) and XRCC3 (Thr241Met) polymorphisms with the risk of breast cancer: a case-control study in Egypt. Genet Test Mol Biomarkers. 2014; 18(11):754-60. DOI: 10.1089/gtmb.2014.0191. View